These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24984010)

  • 1. Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
    Valetti S; Maione F; Mura S; Stella B; Desmaële D; Noiray M; Vergnaud J; Vauthier C; Cattel L; Giraudo E; Couvreur P
    J Control Release; 2014 Oct; 192():29-39. PubMed ID: 24984010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
    Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
    Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
    Bui DT; Nicolas J; Maksimenko A; Desmaële D; Couvreur P
    Chem Commun (Camb); 2014 May; 50(40):5336-8. PubMed ID: 24185552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
    Réjiba S; Reddy LH; Bigand C; Parmentier C; Couvreur P; Hajri A
    Nanomedicine; 2011 Dec; 7(6):841-9. PubMed ID: 21419876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide conjugation: before or after nanoparticle formation?
    Valetti S; Mura S; Noiray M; Arpicco S; Dosio F; Vergnaud J; Desmaële D; Stella B; Couvreur P
    Bioconjug Chem; 2014 Nov; 25(11):1971-83. PubMed ID: 25313527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
    Bildstein L; Dubernet C; Marsaud V; Chacun H; Nicolas V; Gueutin C; Sarasin A; Bénech H; Lepêtre-Mouelhi S; Desmaële D; Couvreur P
    J Control Release; 2010 Oct; 147(2):163-70. PubMed ID: 20691740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
    Singh A; Xu J; Mattheolabakis G; Amiji M
    Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
    Mura S; Buchy E; Askin G; Cayre F; Mougin J; Gouazou S; Sobot D; Valetti S; Stella B; Desmaele D; Couvreur P
    Biochimie; 2016 Nov; 130():4-13. PubMed ID: 27519301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of an amphiphilic squalenoyl prodrug of gemcitabine with cellular membranes.
    Bildstein L; Pili B; Marsaud V; Wack S; Meneau F; Lepêtre-Mouelhi S; Desmaële D; Bourgaux C; Couvreur P; Dubernet C
    Eur J Pharm Biopharm; 2011 Nov; 79(3):612-20. PubMed ID: 21784150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy.
    Qiu W; Zhang H; Chen X; Song L; Cui W; Ren S; Wang Y; Guo K; Li D; Chen R; Wang Z
    Nanomedicine (Lond); 2019 Sep; 14(17):2339-2353. PubMed ID: 31414945
    [No Abstract]   [Full Text] [Related]  

  • 11. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
    Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
    J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.
    Fan F; Jin L; Yang L
    ACS Appl Mater Interfaces; 2021 Mar; 13(11):12824-12835. PubMed ID: 33689289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
    Maksimenko A; Mougin J; Mura S; Sliwinski E; Lepeltier E; Bourgaux C; Lepêtre S; Zouhiri F; Desmaële D; Couvreur P
    Cancer Lett; 2013 Jul; 334(2):346-53. PubMed ID: 22935679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
    Camp ER; Wang C; Little EC; Watson PM; Pirollo KF; Rait A; Cole DJ; Chang EH; Watson DK
    Cancer Gene Ther; 2013 Apr; 20(4):222-8. PubMed ID: 23470564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
    Arias JL; Reddy LH; Couvreur P
    Langmuir; 2008 Jul; 24(14):7512-9. PubMed ID: 18540685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
    Wu L; Zhang F; Chen X; Wan J; Wang Y; Li T; Wang H
    ACS Appl Mater Interfaces; 2020 Jan; 12(3):3327-3340. PubMed ID: 31872760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
    Du C; Qi Y; Zhang Y; Wang Y; Zhao X; Min H; Han X; Lang J; Qin H; Shi Q; Zhang Z; Tian X; Anderson GJ; Zhao Y; Nie G; Yang Y
    ACS Nano; 2018 Nov; 12(11):10785-10796. PubMed ID: 30407790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
    Yin N; Yu H; Zhang X; Lv X
    Drug Des Devel Ther; 2020; 14():4465-4475. PubMed ID: 33122890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
    Oluwasanmi A; Al-Shakarchi W; Manzur A; Aldebasi MH; Elsini RS; Albusair MK; Haxton KJ; Curtis ADM; Hoskins C
    J Control Release; 2017 Nov; 266():355-364. PubMed ID: 28943195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
    Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
    Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.